ATYR NASDAQ
Credit Risk of going bust: higher than 93% of companies Debt: 42.9% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.02 (down 87%), aTyr Pharma, Inc. would be worth roughly what it owes.
Total debt $11.3M against a stock market value of $15.0M.
Distance to default 1.15 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $5.6M (short-term plus half of long-term), stock volatility 110.7%; Altman Z'' -28.37. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
San Diego, CA 92121
US
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Yaras Brandon | A-Award | 410,000 | $0.30 | 2026-10-01 |
| Yaras Brandon | 55,000 | $1.50 | 2026-10-01 | |
| Yaras Brandon | 88,000 | — | 2026-10-01 | |
| SCHIMMEL PAUL | P-Purchase | 100,000 | $0.50 | 2026-05-27 |
| Coughlin Timothy | A-Award | 50,000 | $0.95 | 2026-05-11 |